Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Capital Expenditures of $133.4 million for Q1 2026, up 227.76% year-over-year from $40.7 million in Q1 2025, and down 10.71% quarter-over-quarter from $149.4 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $133.4 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 227.76% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $530.3 million (up 96.41% YoY), while the FY2025 annual figure was $437.6 million, up 46.99% from the prior year.
- Capital Expenditures for Q1 2026 stood at $133.4 million, down from $149.4 million in the prior quarter.
- The five-year high for Capital Expenditures was $149.4 million in Q4 2025, with the low at $33.6 million in Q4 2022.
- The 5-year median for Capital Expenditures is $63.6 million (2022), against an average of $74.9 million.
- The sharpest annual moves came in 2022 and 2026: Capital Expenditures sank 45.63% in 2022, then surged 227.76% in 2026.
- Vertex Pharmaceuticals' Capital Expenditures stood at $33.6 million in 2022, then soared by 72.92% to $58.1 million in 2023, then jumped by 59.38% to $92.6 million in 2024, then jumped by 61.34% to $149.4 million in 2025, then retreated by 10.71% to $133.4 million in 2026.
- Business Quant data shows VRTX's Capital Expenditures at $133.4 million in Q1 2026, $149.4 million in Q4 2025, and $101.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.20 Mn |
| Jun 30, 2026 | 112.20 Mn |
| Mar 31, 2026 | 133.40 Mn |
| Mar 31, 2026 | 133.40 Mn |
| Dec 31, 2025 | 149.40 Mn |
| Dec 31, 2025 | 149.40 Mn |
| Sep 30, 2025 | 101.80 Mn |
| Sep 30, 2025 | 101.80 Mn |
| Jun 30, 2025 | 145.70 Mn |
| Jun 30, 2025 | 145.70 Mn |
| Mar 31, 2025 | 40.70 Mn |
| Mar 31, 2025 | 40.70 Mn |
| Dec 31, 2024 | 92.60 Mn |
| Dec 31, 2024 | 92.60 Mn |
| Sep 30, 2024 | 67.70 Mn |
| Sep 30, 2024 | 67.70 Mn |
| Jun 30, 2024 | 69.00 Mn |
| Jun 30, 2024 | 69.00 Mn |
| Mar 31, 2024 | 68.40 Mn |
| Mar 31, 2024 | 68.40 Mn |